Aquestive Therapeutics, Inc.AQSTEarnings & Financial Report
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for central nervous system disorders. It leverages proprietary drug delivery technologies to create accessible, patient-friendly therapeutic options, serving healthcare providers and patients across North America and European markets, with core offerings addressing unmet needs in neurology and psychiatry.
Revenue
$10.0M
Gross Profit
$5.4M
Operating Profit
$-11.4M
Net Profit
$-13.5M
Gross Margin
54.4%
Operating Margin
-113.6%
Net Margin
-135.4%
YoY Growth
-50.2%
EPS
$-0.14
Aquestive Therapeutics, Inc. Q2 FY2025 Financial Summary
Aquestive Therapeutics, Inc. reported revenue of $10.0M (down 50.2% YoY) for Q2 FY2025, with a net profit of $-13.5M (down 393.6% YoY) (-135.4% margin). Cost of goods sold was $4.6M, operating expenses totaled $16.8M.
Key Financial Metrics
| Total Revenue | $10.0M |
|---|---|
| Net Profit | $-13.5M |
| Gross Margin | 54.4% |
| Operating Margin | -113.6% |
| Report Period | Q2 FY2025 |
Revenue Breakdown
Aquestive Therapeutics, Inc. Q2 FY2025 revenue of $10.0M breaks down across 2 segments, led by Manufacture And Supply Revenue at $9.6M (95.8% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Manufacture And Supply Revenue | $9.6M | 95.8% |
| Other | $420.0K | 4.2% |
Aquestive Therapeutics, Inc. Annual Revenue by Year
Aquestive Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $44.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $44.5M |
| 2024 | $57.6M |
| 2023 | $50.6M |
| 2022 | $47.7M |
Aquestive Therapeutics, Inc. Quarterly Revenue & Net Profit History
Aquestive Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.0M | +9.7% | $-31.9M | -244.8% |
| Q3 FY2025 | $12.8M | -5.4% | $-15.4M | -120.6% |
| Q2 FY2025 | $10.0M | -50.2% | $-13.5M | -135.4% |
| Q1 FY2025 | $8.7M | -27.7% | $-22.9M | -263.0% |
| Q4 FY2024 | $11.9M | -10.1% | $-17.1M | -143.7% |
| Q3 FY2024 | $13.5M | +4.2% | $-11.5M | -85.0% |
| Q2 FY2024 | $20.1M | +51.8% | $-2.7M | -13.7% |
| Q1 FY2024 | $12.1M | +8.3% | $-12.8M | -106.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $20.1M | $13.5M | $11.9M | $8.7M | $10.0M | $12.8M | $13.0M |
| YoY Growth | 8.3% | 51.8% | 4.2% | -10.1% | -27.7% | -50.2% | -5.4% | 9.7% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $129.5M | $117.6M | $110.0M | $101.4M | $102.2M | $93.7M | $163.6M | $160.4M |
| Liabilities | $165.8M | $153.1M | $155.4M | $161.6M | $163.2M | $166.3M | $167.7M | $194.1M |
| Equity | $-36.3M | $-35.5M | $-45.4M | $-60.2M | $-60.9M | $-72.6M | $-4.1M | $-33.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.4M | $-7.0M | $-11.9M | $-6.5M | $-23.4M | $-7.9M | $-12.6M | $-8.5M |